Reata Pharmaceuticals, Inc. The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Eastern District of Texas on behalf of investors who purchased Reata Pharmaceuticals, Inc. (NASDAQ: RETA) securities between October 15, 2019 and August 7, 2020.
According to the Reata lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the MOXIe Part 2 study results were insufficient to support a single study marketing approval of omaveloxolone for the treatment of FA in the U.S. without additional evidence; (ii) as a result, it was foreseeable that the FDA would not accept marketing approval of omaveloxolone for the treatment of FA in the U.S. based on the MOXIe Part 2 study results; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
“Reata Pharmaceuticals, Inc.”
If you suffered a loss in Reata you have until December 14, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
To receive more information, please fill out the form.